Current and future directions for Phase II trials in high-grade glioma

Author： Alexander Brian M   Lee Eudocia Q   Reardon David A   Wen Patrick Y  

Publisher： Informa Healthcare

ISSN： 1473-7175

Source： Expert Review of Neurotherapeutics, Vol.13, Iss.4, 2013-04, pp. : 369-387

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cytotoxic and molecular chemotherapy for high-grade glioma: an emerging strategy for the future

By Cavaliere Robert   Newton Herbert  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 6, 2006-04 ,pp. : 749-765

Informa Healthcare

Access to resources Recommend Favorite

Targeting ErbB Receptors in High-Grade Glioma

By  

Current Pharmaceutical Design, Vol. 17, Iss. 23, 2011-08 ,pp. : 2468-2487

Bentham Science Publishers

Access to resources Recommend Favorite

Carmustine-impregnated wafers and their impact in the management of high-grade glioma

By La Rocca Renato V   Rezazadeh Arash  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 8, 2011-06 ,pp. : 1325-1332

Informa Healthcare

Access to resources Recommend Favorite

Current Issues in Oncology Drug Development, with a Focus on Phase II Trials

By Sargent Daniel  

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 3, 2009-05 ,pp. : 556-562

Taylor & Francis Ltd

Access to resources Recommend Favorite

Vitespen, an investigational cancer vaccine, appears to be beneficial for treating patients with recurrent high-grade glioma

By  

Inpharma, Vol. 1, Iss. 1667, 2008-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite